253 related articles for article (PubMed ID: 29515002)
1. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management.
Sun X; Xiao Z; Chen G; Han Z; Liu Y; Zhang C; Sun Y; Song Y; Wang K; Fang F; Wang X; Lin Y; Xu L; Shao L; Li J; Cheng Z; Gambhir SS; Shen B
Sci Transl Med; 2018 Mar; 10(431):. PubMed ID: 29515002
[TBL] [Abstract][Full Text] [Related]
2. Novel anilino quinazoline-based EGFR tyrosine kinase inhibitors for treatment of non-small cell lung cancer.
Yang L; Liu S; Chu J; Miao S; Wang K; Zhang Q; Wang Y; Xiao Y; Wu L; Liu Y; Yu L; Yu C; Liu X; Ke M; Cheng Z; Sun X
Biomater Sci; 2021 Jan; 9(2):443-455. PubMed ID: 32236267
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of 99mTc-HYNIC-MPG as a novel SPECT radiotracer to detect EGFR-activating mutations in NSCLC.
Xiao Z; Song Y; Kai W; Sun X; Shen B
Oncotarget; 2017 Jun; 8(25):40732-40740. PubMed ID: 28489575
[TBL] [Abstract][Full Text] [Related]
4. Value of
Lv Z; Fan J; Xu J; Wu F; Huang Q; Guo M; Liao T; Liu S; Lan X; Liao S; Geng W; Jin Y
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):735-750. PubMed ID: 29164298
[TBL] [Abstract][Full Text] [Related]
5. Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs.
Yoshida T; Tanaka H; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Iwata H; Hida T; Yatabe Y
Lung Cancer; 2016 Oct; 100():14-19. PubMed ID: 27597275
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons.
Xu D; Yu F; Guo T; Zhou Y; Zhang J; Li Y; Jiang S; Mao J; Yang X; Chu L; Chu X; Wang S; Ni J; Zhu Z
Br J Radiol; 2022 Aug; 95(1136):20220035. PubMed ID: 35611637
[TBL] [Abstract][Full Text] [Related]
7. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
[TBL] [Abstract][Full Text] [Related]
8. CD147-mediated glucose metabolic regulation contributes to the predictive role of
Li X; Fu Q; Zhu Y; Wang J; Liu J; Yu X; Xu W
Mol Carcinog; 2019 Feb; 58(2):247-257. PubMed ID: 30320488
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive decision support for NSCLC treatment using PET/CT radiomics.
Mu W; Jiang L; Zhang J; Shi Y; Gray JE; Tunali I; Gao C; Sun Y; Tian J; Zhao X; Sun X; Gillies RJ; Schabath MB
Nat Commun; 2020 Oct; 11(1):5228. PubMed ID: 33067442
[TBL] [Abstract][Full Text] [Related]
10. The diagnostic and predictive efficacy of
Guo Y; Zhu H; Yao Z; Liu F; Yang D
Eur J Radiol; 2021 Aug; 141():109792. PubMed ID: 34062472
[TBL] [Abstract][Full Text] [Related]
11. Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms.
Shiri I; Maleki H; Hajianfar G; Abdollahi H; Ashrafinia S; Hatt M; Zaidi H; Oveisi M; Rahmim A
Mol Imaging Biol; 2020 Aug; 22(4):1132-1148. PubMed ID: 32185618
[TBL] [Abstract][Full Text] [Related]
12. Radiogenomic Models Using Machine Learning Techniques to Predict EGFR Mutations in Non-Small Cell Lung Cancer.
Nair JKR; Saeed UA; McDougall CC; Sabri A; Kovacina B; Raidu BVS; Khokhar RA; Probst S; Hirsh V; Chankowsky J; Van Kempen LC; Taylor J
Can Assoc Radiol J; 2021 Feb; 72(1):109-119. PubMed ID: 32063026
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.
Guan J; Xiao NJ; Chen M; Zhou WL; Zhang YW; Wang S; Dai YM; Li L; Zhang Y; Li QY; Li XZ; Yang M; Wu HB; Chen LH; Liu LY
Medicine (Baltimore); 2016 Jul; 95(30):e4421. PubMed ID: 27472739
[TBL] [Abstract][Full Text] [Related]
14. Effect of Epidermal Growth Factor Receptor Mutation on Positron Emission Tomography/Computed Tomography in Lung Cancer.
Park JS; Park HY; Choi Y
Anticancer Res; 2024 Jun; 44(6):2681-2687. PubMed ID: 38821597
[TBL] [Abstract][Full Text] [Related]
15. Value of interim
Shao D; Cheng Y; Yuan ZS; Jiang BY; Wang SX
Lung Cancer; 2020 Nov; 149():137-143. PubMed ID: 33011375
[TBL] [Abstract][Full Text] [Related]
16. EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis.
Chen L; Zhou Y; Tang X; Yang C; Tian Y; Xie R; Chen T; Yang J; Jing M; Chen F; Wang C; Sun H; Huang Y
Int J Oncol; 2019 Jan; 54(1):370-380. PubMed ID: 30431083
[TBL] [Abstract][Full Text] [Related]
17. Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non-Small Cell Lung Cancer Detected by
Iommelli F; De Rosa V; Terlizzi C; Monti M; Panico M; Fonti R; Del Vecchio S
Clin Cancer Res; 2018 Jul; 24(13):3126-3136. PubMed ID: 29618618
[No Abstract] [Full Text] [Related]
18. Can
Du B; Wang S; Cui Y; Liu G; Li X; Li Y
BMJ Open; 2021 Jun; 11(6):e044313. PubMed ID: 34103313
[TBL] [Abstract][Full Text] [Related]
19. Identifying advanced stage NSCLC patients who benefit from afatinib therapy using
van de Stadt EA; Yaqub M; Lammertsma AA; Poot AJ; Schuit RC; Remmelzwaal S; Schwarte LA; Smit EF; Hendrikse H; Bahce I
Lung Cancer; 2021 May; 155():156-162. PubMed ID: 33836373
[TBL] [Abstract][Full Text] [Related]
20. [Current Status and Progress in Molecular Imaging of Non-small Cell Lung
Cancer for Molecular Targeted EGFR-TKI Treatment Sensitivity and
Treatment Tolerance Prediction].
Dai D; Xu W; Wang Q; Li X; Zhu Y
Zhongguo Fei Ai Za Zhi; 2017 Dec; 20(12):852-856. PubMed ID: 29277186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]